A Response to: Letter to the Editor Regarding “Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician’s Choice of Treatment in Spain”
Virginia Lozano, Julia Llinares, Patrick Halavacek, Olivia Ashman et autres
es, us, gb, gr (code pays fourni par la source)
0 citations
Oncology and Therapy